The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
MRI contrast agents: Basic chemistry and safety
Abstract
Magnetic resonance imaging (MRI) contrast agents are pharmaceuticals used widely in MRI examinations. Gadolinium‐based MRI contrast agents (GBCAs) are by far the most commonly used. To date, nine GBCAs have been commercialized for clinical use, primarily indicated in the central nervous system, vasculature, and whole body. GBCAs primarily lower the T 1 in vivo to create higher signal in T 1‐weighted MRI scans where GBCAs are concentrated. GBCAs are unique among pharmaceuticals, being water proton relaxation catalysts whose effectiveness is characterized by a rate constant known as relaxivity. The relaxivity of each GBCAs depends on a variety of factors that are discussed in terms of both the existing agents and future molecular imaging agents under study by current researchers. Current GBCAs can be divided into four different structural types (macrocyclic, linear, ionic, and nonionic) based on the chemistry of the chelating ligands whose primary purpose is to protect the body from dissociation of the relatively toxic Gd 3+ ion from the ligand. This article discusses how the chemical structure influences inherent and in vivo stability toward dissociation, and how it affects important formulation properties. Although GBCAs have a lower rate of serious adverse events than iodinated contrast agents, they still present some risk. J. Magn. Reson. Imaging 2012;36:1060–1071. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications
Caravan, P., Ellison, J. J., McMurry, T. J., & Lauffer, R. B. (1999) · Chemical Reviews · doi:10.1021/cr980440x · Cited by 4,483
Rohrer, M., Bauer, H., Mintorovitch, J., Requardt, M., & Weinmann, H.-J. (2005) · Investigative Radiology · doi:10.1097/01.rli.0000184756.66360.d3 · Cited by 1,682
Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent
Weinmann, H., Brasch, R., Press, W., & Wesbey, G. (1984) · American Journal of Roentgenology · doi:10.2214/ajr.142.3.619 · Cited by 1,231
Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation
Sadowski, E. A., Bennett, L. K., Chan, M. R., Wentland, A. L., Garrett, A. L., Garrett, R. W., & Djamali, A. (2007) · Radiology · doi:10.1148/radiol.2431062144 · Cited by 1,018
ACR Guidance Document for Safe MR Practices: 2007
Kanal, E., Barkovich, A. J., Bell, C., Borgstede, J. P., Bradley, W. G., Froelich, J. W., Gilk, T., Gimbel, J. R., Gosbee, J., Kuhni-Kaminski, E., et al. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.1616 · Cited by 787
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
Frenzel, T., Lengsfeld, P., Schirmer, H., Hütter, J., & Weinmann, H.-J. (2008) · Investigative Radiology · doi:10.1097/rli.0b013e3181852171 · Cited by 539
The Design of Molecular Hosts, Guests, and Their Complexes
Cram, D. J. (1988) · Science · doi:10.1126/science.3283937 · Cited by 511
MS-325: albumin-targeted contrast agent for MR angiography.
Lauffer, R. B., Parmelee, D. J., Dunham, S. U., Ouellet, H. S., Dolan, R. P., Witte, S., McMurry, T. J., & Walovitch, R. C. (1998) · Radiology · doi:10.1148/radiology.207.2.9577506 · Cited by 457
Laurent, S., Elst, L. V., & Muller, R. N. (2006) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.100 · Cited by 441
The relationship between thermodynamics and the toxicity of gadolinium complexes
Cacheris, W. P., Quay, S. C., & Rocklage, S. M. (1990) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(90)90055-7 · Cited by 436
Pintaske, J., Martirosian, P., Graf, H., Erb, G., Lodemann, K.-P., Claussen, C. D., & Schick, F. (2006) · Investigative Radiology · doi:10.1097/01.rli.0000197668.44926.f7 · Cited by 383
White, G. W., Gibby, W. A., & Tweedle, M. F. (2006) · Investigative Radiology · doi:10.1097/01.rli.0000186569.32408.95 · Cited by 362
Self-citationNephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
Thomsen, H. S. (2006) · European Radiology · doi:10.1007/s00330-006-0495-8 · Cited by 352
What nephrologists need to know about gadolinium
Penfield, J. G., & Reilly, R. F. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0660 · Cited by 335
Next Generation, High Relaxivity Gadolinium MRI Agents
Raymond, K. N., & Pierre, V. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049817y · Cited by 328
Bioresponsive, Cell-Penetrating, and Multimeric MR Contrast Agents
Major, J. L., & Meade, T. J. (2009) · Accounts of Chemical Research · doi:10.1021/ar800245h · Cited by 321
Ersoy, H., & Rybicki, F. J. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21135 · Cited by 283
MRI Contrast Agents: Current Status and Future Perspectives
Strijkers, G. J., M. Mulder, W. J., F. van Tilborg, G. A., & Nicolay, K. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007780618135 · Cited by 275
Incidence of Immediate Gadolinium Contrast Media Reactions
Prince, M. R., Zhang, H., Zou, Z., Staron, R. B., & Brill, P. W. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.4885 · Cited by 271
MR contrast agents: Physical and pharmacologic basics
Lin, S., & Brown, J. J. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20955 · Cited by 259
Gd-DOTA: characterization of a new paramagnetic complex.
Bousquet, J. C., Saini, S., Stark, D. D., Hahn, P. F., Nigam, M., Wittenberg, J., & Ferrucci, J. T. (1988) · Radiology · doi:10.1148/radiology.166.3.3340763 · Cited by 257
A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRI
Weinmann, H. ‐., Schuhmann‐Giampieri, G., Schmitt‐Willich, H., Vogler, H., Frenzel, T., & Gries, H. (1991) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910220214 · Cited by 237
Sieber, M. A., Pietsch, H., Walter, J., Haider, W., Frenzel, T., & Weinmann, H.-J. (2008) · Investigative Radiology · doi:10.1097/rli.0b013e31815e6277 · Cited by 207
Wertman, R., Altun, E., Martin, D. R., Mitchell, D. G., Leyendecker, J. R., O'Malley, R. B., Parsons, D. J., Fuller, E. R., & Semelka, R. C. (2008) · Radiology · doi:10.1148/radiol.2483072093 · Cited by 187
Idée, J.-M., Port, M., Medina, C., Lancelot, E., Fayoux, E., Ballet, S., & Corot, C. (2008) · Toxicology · doi:10.1016/j.tox.2008.03.012 · Cited by 161
Physicochemical Properties of Gadoteridol and Other Magnetic Resonance Contrast Agents
Tweedle, M. F. (1992) · Investigative Radiology · doi:10.1097/00004424-199208001-00002 · Cited by 158
Self-citationNew Insights into Nephrogenic Systemic Fibrosis
Swaminathan, S., & Shah, S. V. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060645 · Cited by 129
Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA)
Herborn, C. U., Honold, E., Wolf, M., Kemper, J., Kinner, S., Adam, G., & Barkhausen, J. (2007) · Investigative Radiology · doi:10.1097/01.rli.0000248893.01067.e5 · Cited by 126
Schmitt‐Willich, H., Brehm, M., Ewers, C. L. J., Michl, G., Müller‐Fahrnow, A., Petrov, O., Platzek, J., Radüchel, B., & Sülzle, D. (1999) · Inorganic Chemistry · doi:10.1021/ic981072i · Cited by 103
Wedeking, P. W., Sotak, C. H., Telser, J., Kumar, K., Chang, C. A., & Tweedle, M. F. (1992) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(92)90378-d · Cited by 97
Self-citationAbujudeh, H. H., Kosaraju, V., & Kaewlai, R. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3099 · Cited by 91
Involvement of Gadolinium Chelates in the Mechanism of Nephrogenic Systemic Fibrosis: An Update
Idée, J., Port, M., Dencausse, A., Lancelot, E., & Corot, C. (2009) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2009.06.006 · Cited by 90
Pietsch, H., Lengsfeld, P., Steger‐Hartmann, T., Löwe, A., Frenzel, T., Hütter, J. F., & Sieber, M. A. (2009) · Investigative Radiology · doi:10.1097/rli.0b013e3181998eb7 · Cited by 83
Interference of gadodiamide injection (OMNISCAN®) on the colorimetric determination of serum calcium
Normann, P. T., Frøysa, A., & Svaland, M. G. (1995) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519509104981 · Cited by 56
Maurer, M. H., Heine, O., Wolf, M., Durmus, T., Wagner, M., & Hamm, B. (2011) · European Journal of Radiology · doi:10.1016/j.ejrad.2011.04.022 · Cited by 38
Assessment of Adverse Reaction Rates during Gadoteridol-enhanced MR Imaging in 28 078 Patients
Morgan, D. E., Spann, J. S., Lockhart, M. E., Winningham, B., & Bolus, D. N. (2011) · Radiology · doi:10.1148/radiol.10100906 · Cited by 32
Allergic Reactions to Gadolinium Chelates
Runge, V. M. (2001) · American Journal of Roentgenology · doi:10.2214/ajr.177.4.1770944 · Cited by 20
Self-citation
Cited by
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
Hong, G., Diao, S., Antaris, A. L., & Dai, H. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00008 · Cited by 1,394
Intracranial gadolinium deposition after contrast-enhanced MR imaging
McDonald, R. J., McDonald, J. S., Kallmes, D. F., Jentoft, M. E., Murray, D. L., Thielen, K. R., Williamson, E. E., & Eckel, L. J. (2015) · Radiology · doi:10.1148/radiol.15150025 · Cited by 1,358
Kanda, T., Ishii, K., Kawaguchi, H., Kitajima, K., & Takenaka, D. (2014) · Radiology · doi:10.1148/radiol.13131669 · Cited by 1,339
Kanda, T., Fukusato, T., Matsuda, M., Toyoda, K., Oba, H., Kotoku, J., Haruyama, T., Kitajima, K., & Furui, S. (2015) · Radiology · doi:10.1148/radiol.2015142690 · Cited by 874
Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update
Ramalho, J., Semelka, R. C., Ramalho, M., Nunes, R. H., AlObaidy, M., & Castillo, M. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4615 · Cited by 453
Metadata
- Authors
- Hao, D., Ai, T., Goerner, F., Hu, X., Runge, V. M., & Tweedle, M.
- Venue
- Journal of Magnetic Resonance Imaging
- Publisher
- Wiley
- Published
- 2012-10-22
- Volume
- 36
- Issue
- 5
- Pages
- 1060-1071
- ISSN
- 1053-1807 (ISSN-L)
- 1522-2586
- OpenAlex
- W2111481358
- Cited by
- 336
- References
- 37
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.